Education
About Us
Working with TipRanks
Follow Us
Ra Capital Management, Llc Insider Profile
25 Followers
Ra Capital Management, Llc, Former 10% Owner. See FN(1)(6) at Achillion Pharmaceuticals, holds 6.15M shares in Mineralys Therapeutics, Inc. (Ticker: MLYS), holds 11.19M shares in Janux Therapeutics Inc (Ticker: JANX), holds 2.32M shares in Sionna Therapeutics, Inc. (Ticker: SION). Most recently, Ra Capital Management, Llc Bought ― shares of Mineralys Therapeutics, Inc. on Mar 17, 2025 for an estimated value of 17.50M.
Ra Capital Management, Llc Achillion Pharmaceuticals (~ACHN)Former 10% Owner. See FN(1)(6)
Achillion Pharmaceuticals (~ACHN)
Former 10% Owner. See FN(1)(6)
Ranked #89,404 out of 101,080 Corporate Insiders
Profitable Transactions
35 out of 134 Profitable Transactions
Average Return
-5.40%
Average return per transaction
Time Frame
Compare to
Insider Holdings
A breakdown of Ra Capital Management, Llc's holdings
Insider Roles
Roles that Ra Capital Management, Llc holds in companies
Most Profitable Insider Trade
The most profitable trade made by Ra Capital Management, Llc
Ra Capital Management, Llc's Trading History
Achillion Pharmaceuticals
Jan 20, 2015
―
Informative Buy
7.83M
$32.56M
Aclaris Therapeutics
Sep 19, 2016
Ten Percent Owner
Informative Sell
12.71M
$3.32M
KalVista Pharmaceuticals
Oct 16, 2017
Director
Informative Buy
7.22M
$7.38M
Wave Life Sciences
Aug 14, 2024
Director, Ten Percent Owner
Uninformative Buy
―
$185.28M
Ra Pharmaceuticals
Apr 03, 2020
―
Uninformative Sell
233.20M
$0.00
Eidos Therapeutics
Jun 22, 2018
―
Uninformative Buy
―
$264.30M
Arvinas Holding Company
Oct 03, 2018
Former 10% Owner
Uninformative Buy
―
$27.30M
Kala Pharmaceuticals
May 26, 2022
Ten Percent Owner
Informative Sell
362.05K
$49.28M
Thoratec Corp
Dec 13, 2018
―
Uninformative Buy
―
$617.51M
scPharmaceuticals
Mar 16, 2021
Ten Percent Owner
Informative Sell
1.06M
$8.18M
Satsuma Pharmaceuticals
Jun 12, 2023
―
Uninformative Sell
―
$0.00
89bio
Feb 03, 2025
Director, Ten Percent Owner
Informative Buy
50.00M
$173.04M
Synthorx
Jan 24, 2020
―
Uninformative Sell
661.27M
$0.00
Enliven Therapeutics
Feb 27, 2023
Former 10% owner
Uninformative Buy
―
$44.66M
Phathom Pharmaceuticals
Mar 15, 2021
Ten Percent Owner
Informative Sell
31.06M
$15.08M
Verastem
Jun 29, 2020
Ten Percent Owner
Informative Sell
2.22M
$116.71M
Forma Therapeutics Holdings
Oct 14, 2022
―
Uninformative Sell
―
$0.00
Rhythm Pharmaceuticals
Dec 04, 2020
Former 10% Owner
Informative Sell
7.03M
$228.25M
AKOUOS
Jul 02, 2020
―
Uninformative Buy
―
$30.32M
Nkarta
Mar 29, 2024
Director, Ten Percent Owner
Informative Buy
30.00M
$17.50M
Pandion Therapeutics
Jul 22, 2020
―
Uninformative Buy
―
$106.29M
Inozyme Pharma
Jul 28, 2020
Ten Percent Owner
Uninformative Buy
―
$2.04M
iTeos Therapeutics
May 14, 2024
Former 10% Owner
Uninformative Sell
―
$25.89M
Inhibrx
Aug 24, 2020
―
Uninformative Buy
―
$72.62M
TG Therapeutics
Sep 11, 2020
Ten Percent Owner
Informative Sell
4.09M
$518.58M
Dyne Therapeutics
Sep 23, 2020
Ten Percent Owner
Uninformative Buy
―
$34.53M
PMV Pharmaceuticals
Sep 29, 2020
Ten Percent Owner
Uninformative Buy
―
$2.15M
Vaxcyte
Oct 01, 2020
Ten Percent Owner
Informative Sell
11.24M
$397.50M
Orchard Therapeutics
Nov 06, 2020
―
Informative Buy
3.56M
$165.01M
Iterum Therapeutics
Feb 08, 2021
Ten Percent Owner
Uninformative Buy
―
$16.31M
Vor Biopharma
Dec 30, 2024
Director, Ten Percent Owner
Uninformative Buy
―
$34.10M
Solid Biosciences
Jan 12, 2024
Ten Percent Owner
Informative Buy
5.00M
$23.06M
Werewolf Therapeutics
Jan 10, 2023
Director, Ten Percent Owner
Informative Buy
4.10M
$7.19M
Janux Therapeutics Inc
Mar 07, 2025
Director, Ten Percent Owner
Informative Buy
25.34M
$352.59M
Aerovate Therapeutics
Jun 20, 2024
Director, Ten Percent Owner
Informative Buy
1.55M
$22.61M
Acumen Pharmaceuticals
Jul 25, 2023
Director, Ten Percent Owner
Informative Buy
40.00M
$19.11M
POINT Biopharma Global
Jun 30, 2021
―
Informative Buy
2.09M
$13.73M
Cytek Biosciences
Mar 16, 2022
Director, Ten Percent Owner
Uninformative Buy
7.19M
$58.34M
Icosavax
Feb 20, 2024
―
Uninformative Sell
―
$0.00
Climb Bio
Jul 01, 2024
Director, Ten Percent Owner
Uninformative Buy
―
$7.58M
Tyra Bioscience
Nov 13, 2024
Director, Ten Percent Owner
Informative Buy
19.84M
$114.24M
Dice Therapeutics
Aug 09, 2023
―
Uninformative Sell
―
$0.00
AN2 Therapeutics, Inc.
Aug 13, 2024
Ten Percent Owner
Informative Sell
3.81M
$418.19K
PepGen Inc.
Feb 13, 2024
Director, Ten Percent Owner
Informative Buy
27.21M
$25.12M
ARS Pharmaceuticals
Mar 27, 2024
Director, Ten Percent Owner
Informative Buy
13.29M
$124.25M
Fulcrum Therapeutics
Aug 23, 2024
Ten Percent Owner
Uninformative Sell
―
$9.70M
Mineralys Therapeutics, Inc.
Mar 17, 2025
Director
Informative Buy
17.50M
$87.41M
Black Diamond Therapeutics
Jul 07, 2023
Director
Informative Buy
4.68M
$6.03M
LENZ Therapeutics
Mar 25, 2024
Director, Ten Percent Owner
Uninformative Buy
―
$32.78M
Boundless Bio Inc.
Apr 04, 2024
Ten Percent Owner
Uninformative Buy
―
$497.02K
Acrivon Therapeutics, Inc.
Apr 15, 2024
Director, Ten Percent Owner
Uninformative Buy
30.00M
$45.87M
Cidara Therapeutics
Nov 29, 2024
Director
Uninformative Buy
5.81M
$24.34M
Artiva Biotherapeutics, Inc.
Jul 24, 2024
Director, Ten Percent Owner
Uninformative Buy
4.71M
$4.85M
Bicara Therapeutics Inc.
Sep 18, 2024
Director, Ten Percent Owner
Uninformative Buy
―
$35.81M
Septerna, Inc.
Oct 30, 2024
Director, Ten Percent Owner
Uninformative Buy
―
$9.33M
4D Molecular Therapeutics
Dec 10, 2024
Ten Percent Owner
Uninformative Sell
―
$19.07M
Sionna Therapeutics, Inc.
Feb 10, 2025
Director, Ten Percent Owner
Uninformative Buy
―
$34.61M
Sangamo Biosciences
Feb 18, 2015
Former 10% Owner
Informative Buy
―
$5.57M
Biospecifics Technologies
Feb 26, 2010
―
Informative Sell
288.30K
$55.46M
Dicerna Pharma
Feb 05, 2014
―
Informative Buy
15.00M
$193.93M
Sequenom
―
―
―
$27.21M
Curis
―
Ten Percent Owner
―
$18.44M
Derma Sciences
Jan 13, 2014
―
Informative Sell
3.55M
$11.86M
Aradigm
―
―
―
$49.74K
List of latest transactions for each holding click on a transaction to see Ra Capital Management, Llc's performance on stock
You May Also Like
Ra Capital Management, Llc insider profile FAQ
What is the percentage of profitable transactions made by Ra Capital Management, Llc?
The percentage of profitable transactions made by Ra Capital Management, Llc is 26%.
What is the average return per transaction made by Ra Capital Management, Llc?
The average return per transaction made by Ra Capital Management, Llc is -5.40%.
What stocks does Ra Capital Management, Llc hold?
Ra Capital Management, Llc holds: ~ACHN, ACRS, KALV, WVE, RARX, EIDX, ARVN, KALA, ~THOR, SCPH, STSA, ETNB, THOR, ELVN, PHAT, VSTM, FMTX, RYTM, AKUS, NKTX, PAND, INZY, ITOS, ~INBX, TGTX, DYN, PMVP, PCVX, ORTX, ITRM, VOR, SLDB, HOWL, JANX, AVTE, ABOS, PNT, CTKB, ICVX, CLYM, TYRA, DICE, ANTX, PEPG, SPRY, FULC, MLYS, BDTX, LENZ, BOLD, ACRV, CDTX, ARTV, BCAX, SEPN, FDMT, SION, SGMO, BSTC, DRNA, SQNM, CRIS, DSCI, ARDMQ stocks.
What was Ra Capital Management, Llc’s latest transaction?
Ra Capital Management, Llc latest transaction was an Informative Buy of $17.50M.
What was Ra Capital Management, Llc's most profitable transaction?
Ra Capital Management, Llc’s most profitable transaction was an Informative Buy of ETNB stock on July 6, 2022. The return on the trade was 497.40%.
What is Ra Capital Management, Llc's role in Achillion Pharmaceuticals?
Ra Capital Management, Llc's role in Achillion Pharmaceuticals is Former 10% Owner. See FN(1)(6).
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.